Mike Diem

Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York.

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA.

Frantz Medical Ventures (Frantz Medical Ventures) is a venture capital subsidiary of Frantz Medical Group founded in 1979. The firm is headquartered in Mentor, Ohio.

Part of GSK Plc, GlaxoSmithKline North Carolina is a company that develops, manufactures, and markets vaccines and other pharmaceuticals. The company is based in Durham, NC.

Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA.